

TABLE 404-4 Properties of Insulin Preparations^a

PREPARATION	TIME OF ACTION		
	ONSET, h	PEAK, h	EFFECTIVE DURATION, h
Short-acting			
Aspart ^b	<0.25	0.5–1.5	3–5
Glulisine	<0.25	0.5–1.5	3–5
Lispro ^c	<0.25	0.5–1.5	3–5
Regular ^d	0.5–1.0	2–3	4–8
Inhaled human insulin	<0.5	1–2	3
Long-acting			
Degludec	1–9	— ^e	42 ^f
Detemir	1–4	— ^e	12–24 ^f
Glargine ^g	2–4	— ^e	20–24
NPH	2–4	4–10	10–16
Examples of insulin combinations^h			
75/25–75% protamine lispro, 25% lispro	<0.25	Dual ⁱ	10–16
70/30–70% protamine aspart, 30% aspart	<0.25	Dual ⁱ	15–18
50/50–50% protamine lispro, 50% lispro	<0.25	Dual ⁱ	10–16
70/30–70% NPH, 30% regular	0.5–1	Dual ⁱ	10–16
Combination of long-acting insulin and GLP-1 receptor agonist	See text		

^aInjectable insulin preparations (with exception of inhaled formulation) available in the United States; others are available in the United Kingdom and Europe. Standard